Cue Biopharma, Inc.

CUENASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
31.16 USD
↗ 3.37 (12.13%)AT CLOSE (11:59 AM EDT)
31.26
↗ 0.09 (0.30%)
POST MARKET (AS OF 06:22 PM EDT)
Post Market
AS OF 06:22 PM EDT
31.26
↗ 0.09 (0.30%)
🟢Market: OPEN

CUE is currently priced at $28.50. CUE shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, CUE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jul 17, 2026.

Open?$26.86
High?$31.52
Low?$25.70
Prev. Close?$27.79
Volume?122.6K
Avg. Volume?109.7K
VWAP?$29.43
Rel. Volume?1.12x
Bid / Ask
Bid?$26.33 × 100
Ask?$37.05 × 100
Spread?$10.72
Midpoint?$31.69
Valuation & Ratios
Market Cap?116.7M
Shares Out?4.2M
Float?3.5M
Float %?87.6%
P/E Ratio?N/A
P/B Ratio?5.40
EPS?-$4.65
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
29
Market Cap
116.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cuebiopharma.com
Listed
2018-01-02
Address
40 GUEST STREET
BOSTON, MA 02135
Phone: 617-949-2680
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
77
Short Sent.?
61
Piotroski F-Score?2/9Weak
Altman Z-Score?-9.68Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?8.41%Elevated
Short Interest?298.1K
Days to Cover?2.7
Free Float3.5M
Avg Daily Volume111.2K
Settlement Date2026-06-30
Financial Health
Current Ratio?3.57Strong
Quick Ratio?3.57Strong
Cash Ratio?2.22Strong
Debt/Equity?0.05Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
75/100
P/E?
N/A▾
P/B?
Peers
100
S&P
34
5.40FAIR▾
P/S?
Peers
100
S&P
43
3.57FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.6CHEAP▾
EV/Sales?
Peers
100
S&P
59
3.10FAIR▾
Returns & Efficiency
ROE?
S&P
3
-90.4%WEAK▾
ROA?
S&P
3
-63.2%WEAK▾
Cash Flow & Enterprise
FCF?$-24605000
Enterprise Value?$101.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist